News Gilead Sciences, Inc. Mexican S.E.

Stocks

GILD *

US3755581036

Pharmaceuticals

End-of-day quote Mexican S.E. 2026-08-25			5-day change	1st Jan Change
2,520.00 ^MXN	+1.82%		+5.52%	+13.40%

08-25	Wall Street Wants Receipts
08-25	Lakefront Biotherapeutics, Gilead Secure Another Orphan Drug Designation for Skin Disorder Drug in US	MT

All News

Mentions Relevance

08-26	Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences	BU
08-25	Lakefront Biotherapeutics, Gilead Secure Another Orphan Drug Designation for Skin Disorder Drug in US	MT
08-24	Lakefront Gets FDA Orphan Drug Label for Gamgertamig	MT
08-24	Lakefront Biotherapeutics Autoimmune Disorder Pemphigus Treatment Gets FDA Orphan Drug Designation	DJ
08-24	Gilead Sciences, Inc. Receives European Commission Approval for Trodelvy Plus Pembrolizumab in First-Line Metastatic Triple-Negative Breast Cancer	CI
08-24	Gilead Sciences' Trodelvy Gains EU Approval for Breast Cancer	MT
08-24	European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status	BU
08-19	Gilead Sciences Insider Sold Shares Worth $3,853,908, According to a Recent SEC Filing	MT
08-11	Nucleai And Gilead Sciences Advance AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC Collaboration	CI
08-06	Gilead Sciences : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
08-05	Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says	MT
08-05	Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126	MT
08-05	Goldman Sachs Adjusts Price Target on Gilead Sciences to $135 From $130	MT
08-05	RBC Capital Adjusts Gilead Sciences Price Target to $123 From $120, Maintains Sector Perform Rating	MT
08-04	Gilead Sciences : Second Quarter 2026 Summary of Remarks	PU
08-04	Gilead Sciences, Inc., Q2 2026 Earnings Call, Aug 04, 2026
08-04	Gilead Sciences Swings to 2Q Loss on R&D Costs, HIV-Drug Sales Lift Revenue	DJ
08-04	Gilead Sciences Q2 Swings To Adjusted Loss, Revenue Rises	MT
08-04	Gilead: Q2 Earnings Snapshot	AQ
08-04	(GILD) Gilead Sciences Expects Full Year 2026 Adjusted Loss Range of $0.30 - $0.65, vs. FactSet Est of $0.75 Loss	MT
08-04	Earnings Flash (GILD) Gilead Sciences, Inc. Reports Q2 Revenue $7.80B, vs. FactSet Est of $7.40B	MT
08-04	Earnings Flash (GILD) Gilead Sciences, Inc. Posts Q2 Adjusted Loss $6.75 per Share, vs. FactSet Est of $-7.26	MT
08-04	Earnings Flash (GILD) Gilead Sciences, Inc. Posts Q2 Adjusted Loss $6.75 per Share, vs. FactSet Est of $-7.26	MT
08-04	CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results	BU
08-04	Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on August 7, 2025.	CI